YOKNEAM, Israel, April 3, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in April and May:
23rd Annual Needham Virtual Healthcare Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Chairman, Yair Malca, Chief Financial Officer and Spero Theodorou, Chief Medical Officer
Format: Virtual fireside chat moderated by Michael Matson, CFA and Senior Equity Research Analyst and one-on-one meetings
When: Tuesday, April 9 at 8:00 am ET
A live webcast of the presentation can be accessed here.
BNPP Exane 2nd Annual Aesthetics Day
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer, and Dr. Spero Theodorou, Chief Medical Officer
Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings
When: Tuesday, May 21 at 1:30 pm ET
A replay of webcast of the presentation can be accessed here.
Barclays West Coast Bus Trip
Presenters: Yair Malca, Chief Financial Officer
Format: In-person investor bus tour at InMode's North American headquarters
When: Tuesday, May 21
Location: Irvine, CA
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
Last Trade: | US$17.88 |
Daily Change: | -0.03 -0.17 |
Daily Volume: | 633,939 |
Market Cap: | US$1.360B |
September 04, 2024 August 06, 2024 July 31, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB